20240309_am24_abstract_topic_model
This is a BERTopic model. BERTopic is a flexible and modular topic modeling framework that allows for the generation of easily interpretable topics from large datasets.
Usage
To use this model, please install BERTopic:
pip install -U bertopic
You can use the model as follows:
from bertopic import BERTopic
topic_model = BERTopic.load("djordan/20240309_am24_abstract_topic_model")
topic_model.get_topic_info()
Topic overview
- Number of topics: 175
- Number of training documents: 8265
Click here for an overview of all topics.
| Topic ID | Topic Keywords | Topic Frequency | Label |
|---|---|---|---|
| -1 | Immunotherapy and Tumor Microenvironment - - - - | 5 | Immunotherapy and Tumor Microenvironment |
| 0 | Cancer Survival and Healthcare Access - - - - | 3778 | Cancer Survival and Healthcare Access |
| 1 | |||
| Chimeric Antigen Receptor T Cell Therapy for B-Cell Malignancies - - - - | 429 | Chimeric Antigen Receptor T Cell Therapy for B-Cell Malignancies | |
| 2 | Glioblastoma research and treatment - - - - | 186 | Glioblastoma research and treatment |
| 3 | "3D Organoid Culture in Cancer Research" - - - - | 168 | 3D Organoid Culture in Cancer Research |
| 4 | Kras G12C Inhibitors and Resistance - - - - | 160 | Kras G12C Inhibitors and Resistance |
| 5 | |||
| Acute Myeloid Leukemia Treatment and Drug Screening - - - - | 154 | Acute Myeloid Leukemia Treatment and Drug Screening | |
| 6 | Spatial imaging of tissue microenvironments - - - - | 120 | Spatial imaging of tissue microenvironments |
| 7 | Prostate cancer and AR degradation - - - - | 112 | Prostate cancer and AR degradation |
| 8 | Parp Inhibition and DNA Damage Repair - - - - | 110 | Parp Inhibition and DNA Damage Repair |
| 9 | Pancreatic Ductal Adenocarcinoma (PDAC) Microenvironment - - - - | 99 | Pancreatic Ductal Adenocarcinoma Microenvironment |
| 10 | Topoisomerase 1 Inhibitors Adc Development - - - - | 92 | Topoisomerase 1 Inhibitors Adc Development |
| 11 | Hepatocellular Carcinoma Treatment Research - - - - | 85 | Hepatocellular Carcinoma Treatment Research |
| 12 | EGFR-TKIs and Resistance Mechanisms in Non-Small Cell Lung Cancer - - - - | 78 | EGFR-TKIs and Resistance Mechanisms in Non-Small Cell Lung Cancer |
| 13 | Glutamine Metabolism in Cervical Cancer - - - - | 76 | Glutamine Metabolism in Cervical Cancer |
| 14 | |||
| "Nanoparticle-based cancer treatment" - - - - | 67 | Nanoparticle-based cancer treatment | |
| 15 | Bone metastasis in breast cancer - - - - | 56 | Bone metastasis in breast cancer |
| 16 | Microbiome and Immunotherapy in Cancer - - - - | 54 | Microbiome and Immunotherapy in Cancer |
| 17 | Triple Negative Breast Cancer (TNBC) - - - - | 51 | Triple Negative Breast Cancer |
| 18 | |||
| Oral Squamous Cell Carcinoma (OSCC) Research - - - - | 48 | Oral Squamous Cell Carcinoma Research | |
| 19 | Melanoma therapy and Braf inhibitors - - - - | 46 | Melanoma therapy and Braf inhibitors |
| 20 | Immunomodulation of Glioblastoma with Sting Agonism - - - - | 45 | Immunomodulation of Glioblastoma with Sting Agonism |
| 21 | |||
| "Anticancer mechanisms of natural compounds" - - - - | 41 | Anticancer mechanisms of natural compounds | |
| 22 | Renal Cell Carcinoma Subtypes - - - - | 41 | Renal Cell Carcinoma Subtypes |
| 23 | |||
| "Liquid Biopsy Using Urine and Plasma Samples" - - - - | 40 | Liquid Biopsy Using Urine and Plasma Samples | |
| 24 | Award ceremony speech draft - - - - | 39 | Award ceremony speech draft |
| 25 | |||
| TCR-engineered therapy for cancer treatment - - - - | 38 | TCR-engineered therapy for cancer treatment | |
| 26 | T-cell engagers for cancer treatment - - - - | 38 | T-cell engagers for cancer treatment |
| 27 | Colorectal cancer research - - - - | 37 | Colorectal cancer research |
| 28 | Obesity and breast cancer - - - - | 36 | Obesity and breast cancer |
| 29 | Ferroptosis in cancer treatment - - - - | 36 | Ferroptosis in cancer treatment |
| 30 | Trop2-targeted ADCs for cancer treatment - - - - | 34 | Trop2-targeted ADCs for cancer treatment |
| 31 | Hippo pathway inhibitors - - - - | 34 | Hippo pathway inhibitors |
| 32 | Immunotherapy in mice - - - - | 33 | Immunotherapy in mice |
| 33 | |||
| Clinical trials of immunotherapies - - - - | 32 | Clinical trials of immunotherapies | |
| 34 | Immunity checkpoint inhibitors and resistance - - - - | 29 | Immunity checkpoint inhibitors and resistance |
| 35 | Pancreatic cancer research - - - - | 29 | Pancreatic cancer research |
| 36 | Drug combination screening - - - - | 28 | Drug combination screening |
| 37 | |||
| Pancreatic Cancer Research - - - - | 27 | Pancreatic Cancer Research | |
| 38 | Her2 expression in solid tumors - - - - | 26 | Her2 expression in solid tumors |
| 39 | Smoking-induced lung cancer research - - - - | 26 | Smoking-induced lung cancer research |
| 40 | |||
| "Stk11 Loss Drives Anti-PD1 Resistance in Lung Cancer" - - - - | 26 | Stk11 Loss Drives Anti-PD1 Resistance in Lung Cancer | |
| 41 | Prostate cancer research and treatment - - - - | 25 | Prostate cancer research and treatment |
| 42 | Cyclin-dependent kinase 2 inhibition in cancer therapy - - - - | 25 | Cyclin-dependent kinase 2 inhibition in cancer therapy |
| 43 | |||
| "Methylation Detection from Cell-Free DNA" - - - - | 25 | Methylation Detection from Cell-Free DNA | |
| 44 | Medulloblastoma research and treatment - - - - | 25 | Medulloblastoma research and treatment |
| 45 | Single-cell RNA sequencing and chromatin accessibility analysis - - - - | 24 | Single-cell RNA sequencing and chromatin accessibility analysis |
| 46 | |||
| "MTA-PRMT5 Inhibitors for Cancer Treatment" - - - - | 24 | MTA-PRMT5 Inhibitors for Cancer Treatment | |
| 47 | Anti-PD-1 therapy in NSCLC - - - - | 24 | Anti-PD-1 therapy in NSCLC |
| 48 | Immunomodulation with IL-18 and PD-1 antagonists - - - - | 24 | Immunomodulation with IL-18 and PD-1 antagonists |
| 49 | RMS and Pax3-Foxo1 Fusion Protein Research - - - - | 24 | RMS and Pax3-Foxo1 Fusion Protein Research |
| 50 | |||
| "Chromatin organization and gene regulation in breast cancer" - - - - | 24 | Chromatin organization and gene regulation in breast cancer | |
| 51 | Multi-Cancer Early Detection Tests - - - - | 23 | Multi-Cancer Early Detection Tests |
| 52 | |||
| Mitochondrial dysfunction in cancer - - - - | 23 | Mitochondrial dysfunction in cancer | |
| 53 | Cholangiocarcinoma research and treatments - - - - | 23 | Cholangiocarcinoma research and treatments |
| 54 | Immune cell analysis with cytof - - - - | 23 | Immune cell analysis with cytof |
| 55 | |||
| "Circulating Tumor DNA Monitoring in Cancer Treatment" - - - - | 23 | Circulating Tumor DNA Monitoring in Cancer Treatment | |
| 56 | Cellular thermal shift assay (CTSA) for target engagement - - - - | 22 | Cellular thermal shift assay for target engagement |
| 57 | "FFPE Library Prep Methods" - - - - | 21 | FFPE Library Prep Methods |
| 58 | |||
| "Lung Cancer Classification and Targeting" - - - - | 21 | Lung Cancer Classification and Targeting | |
| 59 | Immunotherapy biomarkers in cancer patients - - - - | 20 | Immunotherapy biomarkers in cancer patients |
| 60 | Colorectal cancer genomics and mutations - - - - | 20 | Colorectal cancer genomics and mutations |
| 61 | Epithelial-mesenchymal transition and plasticity in cancer - - - - | 20 | Epithelial-mesenchymal transition and plasticity in cancer |
| 62 | Electric fields for cancer treatment - - - - | 19 | Electric fields for cancer treatment |
| 63 | Cancer-associated fibroblasts in tumor microenvironment - - - - | 19 | Cancer-associated fibroblasts in tumor microenvironment |
| 64 | |||
| Prostate cancer research and diagnosis - - - - | 19 | Prostate cancer research and diagnosis | |
| 65 | |||
| Acquired drug resistance and persister cells - - - - | 19 | Acquired drug resistance and persister cells | |
| 66 | |||
| "EAC and Barrett's Esophagus Research" - - - - | 19 | EAC and Barrett's Esophagus Research | |
| 67 | |||
| "Lung Cancer Research" - - - - | 18 | Lung Cancer Research | |
| 68 | |||
| "Cachexia and Muscle Wasting in Cancer Patients" - - - - | 18 | Cachexia and Muscle Wasting in Cancer Patients | |
| 69 | Cloud-based data governance for cancer research - - - - | 17 | Cloud-based data governance for cancer research |
| 70 | Ewing Sarcoma Research - - - - | 17 | Ewing Sarcoma Research |
| 71 | |||
| "Immunotherapy targeting Tregs" - - - - | 16 | Immunotherapy targeting Tregs | |
| 72 | |||
| Nano-immunotherapy for cancer treatment - - - - | 16 | Nano-immunotherapy for cancer treatment | |
| 73 | |||
| "Trial of T-1101 and T-1201 in Cancer Treatment" - - - - | 16 | Trial of T-1101 and T-1201 in Cancer Treatment | |
| 74 | Radiation and Immunity in Cancer Treatment - - - - | 16 | Radiation and Immunity in Cancer Treatment |
| 75 | Immunotherapy and Neoantigens - - - - | 15 | Immunotherapy and Neoantigens |
| 76 | Aging and immune system in cancer - - - - | 15 | Aging and immune system in cancer |
| 77 | |||
| Progesterone and breast cancer - - - - | 14 | Progesterone and breast cancer | |
| 78 | |||
| "Gut Microbiome in CRC Patients" - - - - | 14 | Gut Microbiome in CRC Patients | |
| 79 | Hematopoiesis and Clonal Variants - - - - | 14 | Hematopoiesis and Clonal Variants |
| 80 | |||
| "Kinase Inhibition and Targeting" - - - - | 14 | Kinase Inhibition and Targeting | |
| 81 | Paralog selective degraders for cancer therapy - - - - | 13 | Paralog selective degraders for cancer therapy |
| 82 | |||
| "Immunotherapy for Melanoma" - - - - | 13 | Immunotherapy for Melanoma | |
| 83 | Genome-scale measurements for tumor normal benchmark - - - - | 13 | Genome-scale measurements for tumor normal benchmark |
| 84 | Immunotherapy for bladder cancer - - - - | 13 | Immunotherapy for bladder cancer |
| 85 | Hematopoietic Progenitor Kinase 1 Inhibition - - - - | 13 | Hematopoietic Progenitor Kinase 1 Inhibition |
| 86 | |||
| Variants of Uncertain Significance (VUS) - - - - | 13 | Variants of Uncertain Significance | |
| 87 | |||
| "Colorectal cancer detection" - - - - | 13 | Colorectal cancer detection | |
| 88 | Claudin18 Targeted Therapy - - - - | 13 | Claudin18 Targeted Therapy |
| 89 | |||
| "AI-based tumor purity analysis" - - - - | 13 | AI-based tumor purity analysis | |
| 90 | Bispecific antibody development for cancer treatment - - - - | 13 | Bispecific antibody development for cancer treatment |
| 91 | |||
| "Genomic Variant Detection" - - - - | 12 | Genomic Variant Detection | |
| 92 | Prostate cancer in African men - - - - | 12 | Prostate cancer in African men |
| 93 | |||
| "Microsatellite Instability and WRN Helicase Inhibition" - - - - | 12 | Microsatellite Instability and WRN Helicase Inhibition | |
| 94 | Immunosuppression and antibody-enhancing drugs - - - - | 12 | Immunosuppression and antibody-enhancing drugs |
| 95 | |||
| "Immune Checkpoint Inhibitor Adverse Events" - - - - | 12 | Immune Checkpoint Inhibitor Adverse Events | |
| 96 | Neuronal influence on cancer growth - - - - | 12 | Neuronal influence on cancer growth |
| 97 | "Uveal Melanoma and Selenoproteome Expression" - - - - | 11 | Uveal Melanoma and Selenoproteome Expression |
| 98 | HBV and HCC Treatment Studies - - - - | 11 | HBV and HCC Treatment Studies |
| 99 | |||
| Btk Inhibitors and Resistance Mechanisms - - - - | 11 | Btk Inhibitors and Resistance Mechanisms | |
| 100 | |||
| "Tertiary Lymphoid Structures in Cancer Prognosis" - - - - | 11 | Tertiary Lymphoid Structures in Cancer Prognosis | |
| 101 | Extrachromosomal DNA in cancer research - - - - | 11 | Extrachromosomal DNA in cancer research |
| 102 | Smarca2/4 degraders for cancer treatment - - - - | 11 | Smarca2/4 degraders for cancer treatment |
| 103 | |||
| "Epigenetic Regulators and Cancer Treatment" - - - - | 11 | Epigenetic Regulators and Cancer Treatment | |
| 104 | Bispecific anti-egfr/cmet adc - - - - | 11 | Bispecific anti-egfr/cmet adc |
| 105 | Transposable elements and cancer - - - - | 10 | Transposable elements and cancer |
| 106 | |||
| "ER Degradation Therapy for Breast Cancer" - - - - | 10 | ER Degradation Therapy for Breast Cancer | |
| 107 | Macrophage-based therapies in cancer - - - - | 10 | Macrophage-based therapies in cancer |
| 108 | |||
| "Genomic Alterations in NSCLC" - - - - | 10 | Genomic Alterations in NSCLC | |
| 109 | Bladder Cancer Diagnosis and Monitoring - - - - | 10 | Bladder Cancer Diagnosis and Monitoring |
| 110 | |||
| "Genomic profiling for cancer diagnosis" - - - - | 10 | Genomic profiling for cancer diagnosis | |
| 111 | TCR Repertoire in Cancer Patients - - - - | 10 | TCR Repertoire in Cancer Patients |
| 112 | Kras Vaccine Development - - - - | 10 | Kras Vaccine Development |
| 113 | |||
| "G-quadruplex Targeting Compound in Pancreatic Cancer Treatment" - - - - | 9 | G-quadruplex Targeting Compound in Pancreatic Cancer Treatment | |
| 114 | |||
| Clinical efficacy of dual Her2 inhibition in metastatic colorectal cancer (MCRC) - - - - | 9 | Clinical efficacy of dual Her2 inhibition in metastatic colorectal cancer | |
| 115 | Liquid biopsy for glioma monitoring - - - - | 9 | Liquid biopsy for glioma monitoring |
| 116 | |||
| Mismatch repair and immune checkpoint inhibitors - - - - | 9 | Mismatch repair and immune checkpoint inhibitors | |
| 117 | |||
| "Immunomodulatory effects of mushroom consumption in prostate cancer." - - - - | 9 | Immunomodulatory effects of mushroom consumption in prostate cancer. | |
| 118 | Nectin-4 targeted ADCs - - - - | 9 | Nectin-4 targeted ADCs |
| 119 | Single-cell gene expression technologies - - - - | 9 | Single-cell gene expression technologies |
| 120 | |||
| Head and neck cancer subtyping - - - - | 9 | Head and neck cancer subtyping | |
| 121 | Cancer Vaccine Development - - - - | 8 | Cancer Vaccine Development |
| 122 | Proteomic analysis of cancer tissues - - - - | 8 | Proteomic analysis of cancer tissues |
| 123 | |||
| "Lymphoma Prognostics and Treatment Strategies" - - - - | 8 | Lymphoma Prognostics and Treatment Strategies | |
| 124 | |||
| "Chemotherapy Resistance Mechanisms in Colorectal Cancer" - - - - | 8 | Chemotherapy Resistance Mechanisms in Colorectal Cancer | |
| 125 | Cancer-associated fibroblasts research - - - - | 7 | Cancer-associated fibroblasts research |
| 126 | |||
| Condensate-based drug discovery - - - - | 7 | Condensate-based drug discovery | |
| 127 | |||
| "Metabolism and Cancer Treatment" - - - - | 7 | Metabolism and Cancer Treatment | |
| 128 | Stat3 degraders for cancer therapy - - - - | 7 | Stat3 degraders for cancer therapy |
| 129 | Melanoma research and embryonic development - - - - | 7 | Melanoma research and embryonic development |
| 130 | |||
| "Ovarian Cancer Biomarkers" - - - - | 7 | Ovarian Cancer Biomarkers | |
| 131 | |||
| LncRNA and Promoter Regulation in Cancer - - - - | 7 | LncRNA and Promoter Regulation in Cancer | |
| 132 | Immunotherapy in cancer treatment - - - - | 7 | Immunotherapy in cancer treatment |
| 133 | |||
| "Ferroptosis in Cancer Cells" - - - - | 7 | Ferroptosis in Cancer Cells | |
| 134 | |||
| "Cdk4 Inhibitors and Breast Cancer Resistance" - - - - | 7 | Cdk4 Inhibitors and Breast Cancer Resistance | |
| 135 | Radiation therapy and DNA damage response inhibitors - - - - | 7 | Radiation therapy and DNA damage response inhibitors |
| 136 | Liquid biopsy for cancer diagnosis and treatment response. - - - - | 7 | Liquid biopsy for cancer diagnosis and treatment response. |
| 137 | Brain Metastasis Survival Analysis - - - - | 7 | Brain Metastasis Survival Analysis |
| 138 | |||
| Molecular Biomarkers in Breast Cancer - - - - | 7 | Molecular Biomarkers in Breast Cancer | |
| 139 | |||
| P53 and RPL22 in Cancer - - - - | 7 | P53 and RPL22 in Cancer | |
| 140 | Colorectal cancer research - - - - | 7 | Colorectal cancer research |
| 141 | |||
| "Tumor Suppression Mechanisms" - - - - | 7 | Tumor Suppression Mechanisms | |
| 142 | Radiation-induced salivary gland damage and regeneration - - - - | 7 | Radiation-induced salivary gland damage and regeneration |
| 143 | |||
| "Adenosine Signaling and Immunotherapy" - - - - | 7 | Adenosine Signaling and Immunotherapy | |
| 144 | Sarcopenia and ICI in NSCLC - - - - | 7 | Sarcopenia and ICI in NSCLC |
| 145 | Ethnic disparities in lymphoma survival - - - - | 7 | Ethnic disparities in lymphoma survival |
| 146 | Liquid biopsy for lung cancer screening - - - - | 7 | Liquid biopsy for lung cancer screening |
| 147 | |||
| "KDM6A Loss in Urothelial Carcinomas" - - - - | 7 | KDM6A Loss in Urothelial Carcinomas | |
| 148 | Immuno-oncology screens with CRISPR and RNA-seq - - - - | 6 | Immuno-oncology screens with CRISPR and RNA-seq |
| 149 | P53 Restoration Therapy - - - - | 6 | P53 Restoration Therapy |
| 150 | Immunometabolic targeting in cancer immunotherapy - - - - | 6 | Immunometabolic targeting in cancer immunotherapy |
| 151 | |||
| "Breast cancer recurrence and gene regulation" - - - - | 6 | Breast cancer recurrence and gene regulation | |
| 152 | Head and neck squamous cell carcinoma (HNSCC) research - - - - | 6 | Head and neck squamous cell carcinoma research |
| 153 | |||
| "HCC Immune Cells Study" - - - - | 6 | HCC Immune Cells Study | |
| 154 | |||
| "Pd-L1 IHC Scoring Methods" - - - - | 6 | Pd-L1 IHC Scoring Methods | |
| 155 | Ovarian Cancer Glycosylation and Metastasis - - - - | 6 | Ovarian Cancer Glycosylation and Metastasis |
| 156 | |||
| "Ubiquitin-Proteasome System in Cancer Treatment" - - - - | 6 | Ubiquitin-Proteasome System in Cancer Treatment | |
| 157 | |||
| Clinical Study of Hbw-3220 and Lp-284 in Aggressive Non-Hodgkin Lymphoma - - - - | 6 | Clinical Study of Hbw-3220 and Lp-284 in Aggressive Non-Hodgkin Lymphoma | |
| 158 | Immunotherapy in Non-Small Cell Lung Cancer - - - - | 6 | Immunotherapy in Non-Small Cell Lung Cancer |
| 159 | Anlotinib + Chemo for Advanced Escc Treatment - - - - | 6 | Anlotinib + Chemo for Advanced Escc Treatment |
| 160 | |||
| "Myc Targeting Technologies" - - - - | 6 | Myc Targeting Technologies | |
| 161 | Neuroblastoma Epigenetics Study - - - - | 5 | Neuroblastoma Epigenetics Study |
| 162 | |||
| "Metastasis and Genetic Alterations" - - - - | 5 | Metastasis and Genetic Alterations | |
| 163 | T Cell Exhaustion and Stemness Programs - - - - | 5 | T Cell Exhaustion and Stemness Programs |
| 164 | |||
| Prostate cancer research - - - - | 5 | Prostate cancer research | |
| 165 | |||
| "Lung Cancer Microenvironment Analysis" - - - - | 5 | Lung Cancer Microenvironment Analysis | |
| 166 | |||
| "Pi3k/Akt Inhibitors in Breast Cancer" - - - - | 5 | Pi3k/Akt Inhibitors in Breast Cancer | |
| 167 | |||
| "Liquid Biopsy Analysis of Whole Blood for Cancer Diagnosis" - - - - | 5 | Liquid Biopsy Analysis of Whole Blood for Cancer Diagnosis | |
| 168 | Extracellular Vesicle Research in Ovarian Cancer - - - - | 5 | Extracellular Vesicle Research in Ovarian Cancer |
| 169 | Colorectal Cancer Secondary Malignancies in Young Adults - - - - | 5 | Colorectal Cancer Secondary Malignancies in Young Adults |
| 170 | Molecular Glues Targeting Cancer-Specific E3 Ligases - - - - | 5 | Molecular Glues Targeting Cancer-Specific E3 Ligases |
| 171 | Epigenetics and Cancer Research - - - - | 5 | Epigenetics and Cancer Research |
| 172 | Immunogenic neoantigens and NMD inhibition in cancer immunotherapy - - - - | 5 | Immunogenic neoantigens and NMD inhibition in cancer immunotherapy |
| 173 | Click Activated Prodrugs Against Cancer Platform - - - - | 5 | Click Activated Prodrugs Against Cancer Platform |
Training hyperparameters
- calculate_probabilities: False
- language: None
- low_memory: False
- min_topic_size: 10
- n_gram_range: (1, 1)
- nr_topics: None
- seed_topic_list: None
- top_n_words: 10
- verbose: True
- zeroshot_min_similarity: 0.7
- zeroshot_topic_list: None
Framework versions
- Numpy: 1.25.2
- HDBSCAN: 0.8.33
- UMAP: 0.5.5
- Pandas: 1.5.3
- Scikit-Learn: 1.2.2
- Sentence-transformers: 2.6.0.dev0
- Transformers: 4.39.0.dev0
- Numba: 0.58.1
- Plotly: 5.15.0
- Python: 3.10.12
- Downloads last month
- 1